CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: benzimidazolylcarbamate fungicide
Accession: CHEBI:87064
browse the term
Definition: Any carbamate fungicide that contains a benzimidazolyl group attached to the nitrogen of the carbamate moiety.
Synonyms: related_synonym: benzimidazolylcarbamate fungicides
G
Adcy7
adenylate cyclase 7
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of ADCY7 mRNA
CTD
PMID:16861626
NCBI chr19:19,702,307...19,762,973
Ensembl chr19:19,704,859...19,727,081
G
Arl4c
ADP ribosylation factor like GTPase 4C
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of ARL4C mRNA
CTD
PMID:16861626
NCBI chr 9:95,783,651...95,787,092
Ensembl chr 9:95,786,508...95,787,094
G
Bag3
BAG cochaperone 3
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of BAG3 mRNA
CTD
PMID:16861626
NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191
G
Ccl2
C-C motif chemokine ligand 2
increases expression
ISO
Albendazole results in increased expression of CCL2 protein
CTD
PMID:20116850
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
G
Ccl3
C-C motif chemokine ligand 3
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of CCL3 protein
CTD
PMID:16861626
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
G
Ccr7
C-C motif chemokine receptor 7
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of CCR7 mRNA
CTD
PMID:16861626
NCBI chr10:87,057,335...87,067,444
Ensembl chr10:87,057,136...87,067,456
G
Cct3
chaperonin containing TCP1 subunit 3
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of CCT3 mRNA
CTD
PMID:16861626
NCBI chr 2:187,669,051...187,693,610
Ensembl chr 2:187,668,796...187,693,610
G
Cd86
CD86 molecule
multiple interactions
ISO
[Albendazole co-treated with CYP3A4 protein] results in increased expression of CD86 protein
CTD
PMID:22785256
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
G
Ctsl
cathepsin L
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of CTSL mRNA
CTD
PMID:16861626
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
increases activity increases expression
ISO
Albendazole results in increased activity of CYP1A1 promoter; Albendazole results in increased activity of CYP1A1 protein Albendazole results in increased expression of CYP1A1 mRNA
CTD
PMID:12451431 PMID:16714371 PMID:18502397
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
increases expression affects metabolic processing
ISO
Albendazole results in increased expression of CYP1A2 mRNA CYP1A2 protein affects the metabolism of Albendazole
CTD
PMID:12451431 PMID:12920490
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
G
Cyp3a62
cytochrome P450, family 3, subfamily a, polypeptide 62
multiple interactions
ISO EXP
[Albendazole co-treated with CYP3A4 protein] results in increased expression of CD86 protein; [Albendazole co-treated with CYP3A4 protein] results in increased expression of ICAM1 protein [SOD2 co-treated with CYP3A4] affects the susceptibility to Albendazole
CTD
PMID:19501153 PMID:22785256
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
G
Dnajb1
DnaJ heat shock protein family (Hsp40) member B1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of DNAJB1 mRNA
CTD
PMID:16861626
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
G
Dpysl2
dihydropyrimidinase-like 2
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of DPYSL2 mRNA
CTD
PMID:16861626
NCBI chr15:43,475,640...43,581,725
Ensembl chr15:43,477,629...43,542,939
G
Gem
GTP binding protein overexpressed in skeletal muscle
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of GEM mRNA
CTD
PMID:16861626
NCBI chr 5:25,339,479...25,353,661
Ensembl chr 5:25,349,928...25,353,661
G
Gpr183
G protein-coupled receptor 183
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of GPR183 mRNA
CTD
PMID:16861626
NCBI chr15:108,364,701...108,376,221
Ensembl chr15:108,364,701...108,376,221
G
Hsp90aa1
heat shock protein 90 alpha family class A member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSP90AA1 mRNA
CTD
PMID:16861626
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775 Ensembl chr 6:135,107,271...135,112,775
G
Hsp90ab1
heat shock protein 90 alpha family class B member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSP90AB1 mRNA
CTD
PMID:16861626
NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
G
Hspa4
heat shock protein family A (Hsp70) member 4
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSPA4 mRNA
CTD
PMID:16861626
NCBI chr10:38,601,624...38,642,397
Ensembl chr10:38,601,624...38,642,397
G
Hspa8
heat shock protein family A (Hsp70) member 8
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSPA8 mRNA
CTD
PMID:16861626
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
G
Hspd1
heat shock protein family D (Hsp60) member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSPD1 mRNA
CTD
PMID:16861626
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
G
Hspe1
heat shock protein family E (Hsp10) member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSPE1 mRNA
CTD
PMID:16861626
NCBI chr 9:61,691,246...61,724,948
Ensembl chr 9:61,692,154...61,694,599
G
Hsph1
heat shock protein family H (Hsp110) member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of HSPH1 mRNA
CTD
PMID:16861626
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
G
Icam1
intercellular adhesion molecule 1
multiple interactions
ISO
[Albendazole co-treated with CYP3A4 protein] results in increased expression of ICAM1 protein
CTD
PMID:22785256
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
G
Il10
interleukin 10
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of IL10 protein
CTD
PMID:16861626
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
G
Il1a
interleukin 1 alpha
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of IL1A protein
CTD
PMID:16861626
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
G
Il1r1
interleukin 1 receptor type 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of IL1R1 mRNA
CTD
PMID:16861626
NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
G
Il6r
interleukin 6 receptor
increases expression
ISO
Albendazole results in increased expression of IL6R protein modified form
CTD
PMID:20116850
NCBI chr 2:189,196,180...189,255,987
Ensembl chr 2:189,205,701...189,254,628
G
Map3k8
mitogen-activated protein kinase kinase kinase 8
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of MAP3K8 mRNA
CTD
PMID:16861626
NCBI chr17:56,109,403...56,129,925
Ensembl chr17:56,109,549...56,129,919
G
Mapt
microtubule-associated protein tau
decreases expression
ISO
Albendazole results in decreased expression of MAPT mRNA; Albendazole results in decreased expression of MAPT protein
CTD
PMID:16930453
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
G
Nr1h4
nuclear receptor subfamily 1, group H, member 4
multiple interactions
ISO
Albendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
CTD
PMID:25257666
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
G
Ppid
peptidylprolyl isomerase D
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of PPID mRNA
CTD
PMID:16861626
NCBI chr 2:178,354,830...178,366,843
Ensembl chr 2:178,354,890...178,366,685
G
Ppif
peptidylprolyl isomerase F
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of PPIF mRNA
CTD
PMID:16861626
NCBI chr16:1,979,191...1,985,912
Ensembl chr16:1,979,191...1,985,908
G
Ptges3
prostaglandin E synthase 3
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of PTGES3 mRNA
CTD
PMID:16861626
NCBI chr 7:2,479,267...2,497,024
Ensembl chr 7:2,479,311...2,497,013
G
RT1-DMb
RT1 class II, locus DMb
affects expression
ISO
Albendazole affects the expression of HLA-DMB mRNA
CTD
PMID:25811541
NCBI chr20:3,945,383...3,952,838
Ensembl chr20:5,227,045...5,234,290 Ensembl chr20:5,227,045...5,234,290
G
Skap2
src kinase associated phosphoprotein 2
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of SKAP2 mRNA
CTD
PMID:16861626
NCBI chr 4:81,816,778...81,968,832
Ensembl chr 4:81,818,569...81,968,832
G
Sod2
superoxide dismutase 2
multiple interactions
EXP
[SOD2 co-treated with CYP3A4] affects the susceptibility to Albendazole
CTD
PMID:19501153
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
G
Sphk1
sphingosine kinase 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of SPHK1 mRNA
CTD
PMID:16861626
NCBI chr10:105,498,728...105,504,401
Ensembl chr10:105,498,728...105,504,393
G
St13
ST13, Hsp70 interacting protein
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of ST13 mRNA
CTD
PMID:16861626
NCBI chr 7:122,585,770...122,635,731
Ensembl chr 7:122,585,771...122,635,731
G
Tcp1
t-complex 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in increased expression of TCP1 mRNA
CTD
PMID:16861626
NCBI chr 1:48,025,664...48,033,343
Ensembl chr 1:48,025,663...48,033,396
G
Tgif1
TGFB-induced factor homeobox 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of TGIF1 mRNA
CTD
PMID:16861626
NCBI chr 9:119,181,079...119,190,698
Ensembl chr 9:119,181,083...119,190,698
G
Tnf
tumor necrosis factor
multiple interactions increases secretion
ISO
U 0126 inhibits the reaction [Albendazole results in increased secretion of TNF protein]
CTD
PMID:20848085
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
G
Tsc22d1
TSC22 domain family, member 1
multiple interactions
ISO
[Ivermectin co-treated with Albendazole] results in decreased expression of TSC22D1 mRNA
CTD
PMID:16861626
NCBI chr15:58,554,358...58,658,156
Ensembl chr15:58,554,374...58,658,153
G
Vegfa
vascular endothelial growth factor A
increases expression
ISO
Albendazole results in increased expression of VEGFA protein
CTD
PMID:20116850
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
G
Abcg2
ATP binding cassette subfamily G member 2
affects transport
ISO
ABCG2 protein affects the transport of albendazole sulfoxide
CTD
PMID:15703302
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
G
Nr1h4
nuclear receptor subfamily 1, group H, member 4
multiple interactions
ISO
albendazole sulfoxide inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
CTD
PMID:25257666
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
G
Adam33
ADAM metallopeptidase domain 33
multiple interactions increases expression
ISO
ORMDL3 protein affects the reaction [Benomyl results in increased expression of ADAM33 protein]
CTD
PMID:27784618
NCBI chr 3:123,595,018...123,607,549
Ensembl chr 3:123,595,560...123,607,352
G
Aldh2
aldehyde dehydrogenase 2 family member
decreases activity
ISO EXP
Benomyl metabolite results in decreased activity of ALDH2 protein; Benomyl results in decreased activity of ALDH2 protein
CTD
PMID:9585485 PMID:10513990 PMID:11142365 PMID:15331769 PMID:17010440
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
G
Aldh5a1
aldehyde dehydrogenase 5 family, member A1
decreases activity
EXP
Benomyl results in decreased activity of ALDH5A1 protein
CTD
PMID:17010440
NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
G
Ampd3
adenosine monophosphate deaminase 3
decreases expression
EXP
Benomyl results in decreased expression of AMPD3 mRNA
CTD
PMID:15885261
NCBI chr 1:175,585,301...175,630,479
Ensembl chr 1:175,586,097...175,630,467
G
Ar
androgen receptor
multiple interactions
ISO
Benomyl inhibits the reaction [Dihydrotestosterone affects the localization of and results in increased phosphorylation of AR protein]
CTD
PMID:25324206
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
G
Bax
BCL2 associated X, apoptosis regulator
multiple interactions
ISO
Benomyl inhibits the reaction [BCL2 protein binds to BAX protein]
CTD
PMID:16903866
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
G
Bcl2
BCL2, apoptosis regulator
multiple interactions increases phosphorylation
ISO
Benomyl inhibits the reaction [BCL2 protein binds to BAX protein] Benomyl results in increased phosphorylation of BCL2 protein
CTD
PMID:16903866
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
G
Bub1b
BUB1 mitotic checkpoint serine/threonine kinase B
increases expression
ISO
Benomyl results in increased expression of BUB1B protein
CTD
PMID:16903866
NCBI chr 3:110,367,949...110,420,471
Ensembl chr 3:110,367,939...110,420,458
G
Car2
carbonic anhydrase 2
increases expression
EXP
Benomyl results in increased expression of CA2 mRNA
CTD
PMID:15885261
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
G
Ccl17
C-C motif chemokine ligand 17
increases expression multiple interactions
ISO
Benomyl results in increased expression of CCL17 mRNA ORMDL3 protein affects the reaction [Benomyl results in increased expression of CCL17 mRNA]
CTD
PMID:27784618
NCBI chr19:10,619,220...10,620,671
Ensembl chr19:10,619,220...10,620,671
G
Ccnb1
cyclin B1
increases response to substance
ISO
CCNB1 protein results in increased susceptibility to Benomyl
CTD
PMID:11960377
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
G
Ccnb2
cyclin B2
increases response to substance
ISO
CCNB2 protein results in increased susceptibility to Benomyl
CTD
PMID:11960377
NCBI chr 8:76,847,972...76,861,165
G
Cd38
CD38 molecule
decreases expression
EXP
Benomyl results in decreased expression of CD38 mRNA
CTD
PMID:15885261
NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
G
Cyp17a1
cytochrome P450, family 17, subfamily a, polypeptide 1
decreases expression multiple interactions
ISO
Benomyl results in decreased expression of CYP17A1 mRNA Benomyl results in decreased expression of and results in decreased activity of CYP17A1 protein
CTD
PMID:25324206
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
G
Cyp19a1
cytochrome P450, family 19, subfamily a, polypeptide 1
increases activity increases expression
ISO
Benomyl results in increased activity of CYP19A1 protein Benomyl results in increased expression of CYP19A1 mRNA
CTD
PMID:14691014 PMID:25543211
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
G
Ddit3
DNA-damage inducible transcript 3
multiple interactions increases expression
ISO
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of DDIT3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of DDIT3 protein]
CTD
PMID:27784618
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
G
Eif2ak3
eukaryotic translation initiation factor 2 alpha kinase 3
increases expression multiple interactions
ISO
Benomyl results in increased expression of EIF2AK3 protein Acetylcysteine inhibits the reaction [Benomyl results in increased expression of EIF2AK3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of EIF2AK3 protein]
CTD
PMID:27784618
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
G
Ern1
endoplasmic reticulum to nucleus signaling 1
multiple interactions increases expression
ISO
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of ERN1 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of ERN1 protein]
CTD
PMID:27784618
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
G
Esr1
estrogen receptor 1
multiple interactions affects binding
ISO
Benomyl binds to and results in increased activity of ESR1 protein; Benomyl inhibits the reaction [Estradiol binds to ESR1 protein] Benomyl binds to ESR1 protein
CTD
PMID:14579009 PMID:16626760
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
G
Fgfr4
fibroblast growth factor receptor 4
increases expression
EXP
Benomyl results in increased expression of FGFR4 mRNA
CTD
PMID:15885261
NCBI chr17:9,990,072...10,004,339
Ensembl chr17:9,990,078...10,004,321
G
Gipc1
GIPC PDZ domain containing family, member 1
increases expression
EXP
Benomyl results in increased expression of GIPC1 mRNA
CTD
PMID:15885261
NCBI chr19:24,786,604...24,798,231
Ensembl chr19:24,786,628...24,798,233
G
Glyat
glycine-N-acyltransferase
increases expression
EXP
Benomyl results in increased expression of GLYAT mRNA
CTD
PMID:15885261
NCBI chr 1:229,060,125...229,081,113
Ensembl chr 1:229,063,714...229,080,410
G
Hdac1
histone deacetylase 1
decreases activity
ISO
Benomyl results in decreased activity of HDAC1 protein
CTD
PMID:25543211
NCBI chr 5:147,716,664...147,743,723
Ensembl chr 5:147,716,664...147,743,723
G
Hspa5
heat shock protein family A (Hsp70) member 5
increases expression multiple interactions
ISO
Benomyl results in increased expression of HSPA5 protein Acetylcysteine inhibits the reaction [Benomyl results in increased expression of HSPA5 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of HSPA5 protein]
CTD
PMID:27784618
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
G
Hspb1
heat shock protein family B (small) member 1
increases expression
EXP
Benomyl results in increased expression of HSPB1 mRNA
CTD
PMID:15885261
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
G
Ifnb1
interferon beta 1
multiple interactions
ISO
Benomyl inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]
CTD
PMID:18177342
NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
G
Itga5
integrin subunit alpha 5
decreases expression
ISO
Benomyl results in decreased expression of ITGA5 mRNA
CTD
PMID:25530041
NCBI chr 7:144,970,444...144,993,652
Ensembl chr 7:144,970,444...144,993,652
G
Itgb1
integrin subunit beta 1
decreases expression
ISO
Benomyl results in decreased expression of ITGB1 mRNA
CTD
PMID:25530041
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
G
Mmp2
matrix metallopeptidase 2
decreases expression multiple interactions increases expression
ISO
Benomyl results in decreased expression of MMP2 mRNA ORMDL3 protein affects the reaction [Benomyl results in increased expression of MMP2 protein]
CTD
PMID:25530041 PMID:27784618
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
G
Mmp9
matrix metallopeptidase 9
decreases expression
EXP ISO
Benomyl results in decreased expression of MMP9 protein Benomyl results in decreased expression of MMP9 mRNA
CTD
PMID:10026946 PMID:25530041
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
G
Mmrn1
multimerin 1
increases expression
EXP
Benomyl results in increased expression of MMRN1 mRNA
CTD
PMID:15885261
NCBI chr 4:90,977,537...91,038,747
Ensembl chr 4:90,990,088...91,038,748
G
Msmb
microseminoprotein, beta
increases expression
EXP
Benomyl results in increased expression of MSMB mRNA
CTD
PMID:15885261
NCBI chr16:8,280,275...8,300,853
Ensembl chr16:8,280,275...8,300,852
G
Mt2A
metallothionein 2A
increases expression
EXP
Benomyl results in increased expression of MT2A mRNA
CTD
PMID:15885261
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
G
Nfkb1
nuclear factor kappa B subunit 1
multiple interactions
ISO
Benomyl inhibits the reaction [Lipopolysaccharides results in increased activity of NFKB1 protein]
CTD
PMID:17015962
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
G
Nr1h4
nuclear receptor subfamily 1, group H, member 4
multiple interactions
ISO
Benomyl inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
CTD
PMID:25257666
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
G
Olr1346
olfactory receptor 1346
increases expression
EXP
Benomyl results in increased expression of OLR1346 mRNA
CTD
PMID:15885261
NCBI chr 9:99,720,856...99,721,827
Ensembl chr 9:99,720,856...99,721,827
G
Olr1700
olfactory receptor 1700
increases expression
EXP
Benomyl results in increased expression of OLR1700 mRNA
CTD
PMID:15885261
NCBI chr20:1,089,163...1,090,128
Ensembl chr20:1,098,343...1,099,336
G
Olr857
olfactory receptor 857
increases expression
EXP
Benomyl results in increased expression of OLR857 mRNA
CTD
PMID:15885261
NCBI chr 5:137,738,298...137,739,246
Ensembl chr 5:137,738,298...137,739,246 Ensembl chr 5:137,738,298...137,739,246
G
Ormdl3
ORMDL sphingolipid biosynthesis regulator 3
multiple interactions increases expression
ISO
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of ORMDL3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of ORMDL3 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of ADAM33 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of CCL17 mRNA]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of CXCL8 mRNA]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of MMP2 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of TSLP mRNA]
CTD
PMID:27784618
NCBI chr10:86,545,910...86,554,478
Ensembl chr10:86,547,339...86,554,478
G
Parp1
poly (ADP-ribose) polymerase 1
increases cleavage
ISO
Benomyl results in increased cleavage of PARP1 protein
CTD
PMID:16903866
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
G
Plau
plasminogen activator, urokinase
decreases expression
ISO
Benomyl results in decreased expression of PLAU mRNA
CTD
PMID:25530041
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
G
Scd
stearoyl-CoA desaturase
decreases expression
EXP
Benomyl results in decreased expression of SCD1 mRNA
CTD
PMID:15885261
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
G
Serpine2
serpin family E member 2
increases expression
ISO
Benomyl results in increased expression of SERPINE2 mRNA
CTD
PMID:25530041
NCBI chr 9:85,560,852...85,629,410
Ensembl chr 9:85,560,863...85,626,094
G
Sh2d4a
SH2 domain containing 4A
increases expression
EXP
Benomyl results in increased expression of SH2D4A mRNA
CTD
PMID:15885261
NCBI chr16:23,084,247...23,156,825
Ensembl chr16:23,083,954...23,156,962
G
Timp1
TIMP metallopeptidase inhibitor 1
increases expression
ISO
Benomyl results in increased expression of TIMP1 mRNA
CTD
PMID:25530041
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
G
Timp2
TIMP metallopeptidase inhibitor 2
increases expression
ISO
Benomyl results in increased expression of TIMP2 mRNA
CTD
PMID:25530041
NCBI chr10:107,338,465...107,386,072
Ensembl chr10:107,338,465...107,386,072
G
Tslp
thymic stromal lymphopoietin
increases expression multiple interactions
ISO
Benomyl results in increased expression of TSLP mRNA ORMDL3 protein affects the reaction [Benomyl results in increased expression of TSLP mRNA]
CTD
PMID:27784618
NCBI chr18:25,613,601...25,618,066
Ensembl chr18:25,613,831...25,617,361
G
Uba1
ubiquitin-like modifier activating enzyme 1
multiple interactions
ISO
Benomyl results in increased activity of and results in increased ubiquitination of UBA1 protein
CTD
PMID:25714994
NCBI chr X:1,723,135...1,745,147
Ensembl chr X:1,723,174...1,741,701
G
Vasp
vasodilator-stimulated phosphoprotein
multiple interactions
EXP
Benomyl inhibits the reaction [Nitroglycerin results in increased phosphorylation of VASP protein]; Benomyl inhibits the reaction [Pentaerythritol Tetranitrate results in increased phosphorylation of VASP protein]
CTD
PMID:15331769
NCBI chr 1:80,170,608...80,185,882
Ensembl chr 1:80,170,619...80,185,882
G
Abi2
abl-interactor 2
increases expression
EXP
carbendazim results in increased expression of ABI2 mRNA
CTD
PMID:22952946
NCBI chr 9:67,234,612...67,284,504
Ensembl chr 9:67,234,303...67,282,600
G
Acaca
acetyl-CoA carboxylase alpha
increases expression
ISO
carbendazim results in increased expression of ACACA mRNA
CTD
PMID:26071454
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
G
Ache
acetylcholinesterase
multiple interactions
EXP
[carbendazim co-treated with mancozeb] results in increased activity of ACHE protein
CTD
PMID:33217513
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
G
Agpat2
1-acylglycerol-3-phosphate O-acyltransferase 2
increases expression
ISO
carbendazim results in increased expression of AGPAT2 mRNA
CTD
PMID:26071454
NCBI chr 3:4,044,741...4,055,384
Ensembl chr 3:4,044,542...4,055,806
G
Ahr
aryl hydrocarbon receptor
multiple interactions affects localization
ISO
AHR protein affects the reaction [carbendazim results in increased expression of CYP1A1 protein] carbendazim affects the localization of AHR protein
CTD
PMID:27286660
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
G
Anxa10
annexin A10
increases expression
ISO
carbendazim results in increased expression of ANXA10 mRNA
CTD
PMID:32194361
NCBI chr16:29,674,699...29,741,521
Ensembl chr16:29,674,793...29,741,465
G
Arg1
arginase 1
decreases expression
ISO
carbendazim results in decreased expression of ARG1 mRNA
CTD
PMID:32194361
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
G
Bag1
BAG cochaperone 1
increases expression
EXP
carbendazim results in increased expression of BAG1 mRNA
CTD
PMID:22952946
NCBI chr 5:57,254,421...57,267,002
Ensembl chr 5:57,254,421...57,267,002
G
Bcl2l14
BCL2 like 14
increases expression
EXP
carbendazim results in increased expression of BCL2L14 mRNA
CTD
PMID:22952946
NCBI chr 4:168,139,964...168,183,726
Ensembl chr 4:168,142,271...168,183,096
G
Casp3
caspase 3
increases activity
ISO
carbendazim results in increased activity of CASP3 protein
CTD
PMID:30851412
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
G
Clca2
chloride channel accessory 2
multiple interactions
EXP
[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of CLCA2 mRNA
CTD
PMID:22382377
NCBI chr 2:250,954,423...250,981,544
Ensembl chr 2:250,954,397...250,981,623
G
Cldn11
claudin 11
multiple interactions
EXP
[carbendazim co-treated with iprodione] results in decreased expression of CLDN11 protein
CTD
PMID:28576679
NCBI chr 2:115,823,541...115,836,846
Ensembl chr 2:115,823,538...115,836,846
G
Clu
clusterin
decreases expression increases expression
EXP
carbendazim results in decreased expression of CLU mRNA carbendazim results in increased expression of CLU mRNA
CTD
PMID:22952946 PMID:27466211
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
G
Cyp19a1
cytochrome P450, family 19, subfamily a, polypeptide 1
increases activity increases expression
ISO
carbendazim results in increased activity of CYP19A1 protein carbendazim results in increased expression of CYP19A1 mRNA
CTD
PMID:14691014
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
increases expression multiple interactions
ISO EXP
carbendazim results in increased expression of CYP1A1 mRNA; carbendazim results in increased expression of CYP1A1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [carbendazim results in increased expression of CYP1A1 protein]; AHR protein affects the reaction [carbendazim results in increased expression of CYP1A1 protein]; salicylamide inhibits the reaction [carbendazim results in increased expression of CYP1A1 protein]
CTD
PMID:10103034 PMID:21784029 PMID:27286660 PMID:32194361
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
increases expression
ISO
carbendazim results in increased expression of CYP1A2 mRNA; carbendazim results in increased expression of CYP1A2 protein
CTD
PMID:21784029
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
G
Cyp2b3
cytochrome P450, family 2, subfamily b, polypeptide 3
increases expression
ISO
carbendazim results in increased expression of CYP2B6 mRNA
CTD
PMID:22310298
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
G
Cyp2c6v1
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1
decreases expression
ISO
carbendazim results in decreased expression of CYP2C19 protein
CTD
PMID:32194361
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
G
Cyp2d4
cytochrome P450, family 2, subfamily d, polypeptide 4
decreases activity
ISO
carbendazim results in decreased activity of CYP2D6 protein
CTD
PMID:20183062
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
G
Cyp3a62
cytochrome P450, family 3, subfamily a, polypeptide 62
increases expression
ISO
carbendazim results in increased expression of CYP3A4 mRNA
CTD
PMID:22310298
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
G
Cyp7a1
cytochrome P450 family 7 subfamily A member 1
decreases expression
ISO
carbendazim results in decreased expression of CYP7A1 mRNA; carbendazim results in decreased expression of CYP7A1 protein
CTD
PMID:32194361
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
G
Dgat1
diacylglycerol O-acyltransferase 1
increases expression
ISO
carbendazim results in increased expression of DGAT1 mRNA
CTD
PMID:26071454
NCBI chr 7:117,566,363...117,576,735
Ensembl chr 7:117,566,368...117,576,737
G
Dgat2
diacylglycerol O-acyltransferase 2
increases expression
ISO
carbendazim results in increased expression of DGAT2 mRNA
CTD
PMID:26071454
NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
G
Dnaaf11
dynein axonemal assembly factor 11
decreases expression
EXP
carbendazim results in decreased expression of DNAAF11 mRNA
CTD
PMID:27466211
NCBI chr 7:107,130,402...107,231,507
Ensembl chr 7:107,130,402...107,223,047
G
Dpp7
dipeptidylpeptidase 7
multiple interactions
EXP
[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of DPP7 mRNA
CTD
PMID:22382377
NCBI chr 3:2,569,135...2,573,387
Ensembl chr 3:2,569,135...2,573,387
G
Esr1
estrogen receptor 1
decreases expression
EXP
carbendazim results in decreased expression of ESR1 mRNA
CTD
PMID:28576679
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
G
Esr2
estrogen receptor 2
decreases expression
EXP
carbendazim results in decreased expression of ESR2 mRNA
CTD
PMID:28576679
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
G
Fank1
fibronectin type III and ankyrin repeat domains 1
increases expression
EXP
carbendazim results in increased expression of FANK1 mRNA
CTD
PMID:22952946
NCBI chr 1:205,842,469...205,954,152
Ensembl chr 1:205,842,489...205,950,371
G
Foxa2
forkhead box A2
increases expression
ISO
carbendazim results in increased expression of FOXA2 mRNA
CTD
PMID:26071454
NCBI chr 3:142,383,084...142,387,493
Ensembl chr 3:142,383,278...142,387,481
G
G6pc1
glucose-6-phosphatase catalytic subunit 1
decreases expression
ISO
carbendazim results in decreased expression of G6PC1 mRNA
CTD
PMID:32194361
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
G
Gja1
gap junction protein, alpha 1
multiple interactions
EXP
[carbendazim co-treated with iprodione] results in decreased expression of GJA1 protein
CTD
PMID:28576679
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
G
Ift81
intraflagellar transport 81
decreases expression
EXP
carbendazim results in decreased expression of IFT81 mRNA
CTD
PMID:22952946 PMID:27466211
NCBI chr12:39,420,161...39,507,412
Ensembl chr12:39,423,596...39,506,890
G
Il1b
interleukin 1 beta
increases expression
ISO
carbendazim results in increased expression of IL1B mRNA; carbendazim results in increased expression of IL1B protein
CTD
PMID:26071454
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
G
Il6
interleukin 6
increases expression
ISO
carbendazim results in increased expression of IL6 mRNA; carbendazim results in increased expression of IL6 protein
CTD
PMID:26071454
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
G
Itga5
integrin subunit alpha 5
decreases expression
ISO
carbendazim results in decreased expression of ITGA5 mRNA
CTD
PMID:25530041
NCBI chr 7:144,970,444...144,993,652
Ensembl chr 7:144,970,444...144,993,652
G
Itgb1
integrin subunit beta 1
decreases expression
ISO
carbendazim results in decreased expression of ITGB1 mRNA
CTD
PMID:25530041
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
G
Loxl1
lysyl oxidase-like 1
multiple interactions increases expression
EXP
2,5-hexanedione promotes the reaction [carbendazim results in increased expression of LOXL1 protein]; [carbendazim co-treated with 2,5-hexanedione] results in decreased expression of LOXL1 mRNA
CTD
PMID:22382377
NCBI chr 8:63,067,757...63,092,124
Ensembl chr 8:63,067,300...63,092,009
G
Lpl
lipoprotein lipase
decreases expression
ISO
carbendazim results in decreased expression of LPL protein
CTD
PMID:30496565
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
G
Macrod1
mono-ADP ribosylhydrolase 1
multiple interactions
EXP
[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of MACROD1 mRNA
CTD
PMID:22382377
NCBI chr 1:222,310,916...222,451,485
Ensembl chr 1:222,310,920...222,451,484
G
Mfap3l
microfibril associated protein 3 like
increases expression
EXP
carbendazim results in increased expression of MFAP3L mRNA
CTD
PMID:22952946
NCBI chr16:32,734,059...32,777,091
Ensembl chr16:32,738,265...32,753,278
G
Mir128-1
microRNA 128-1
increases expression
EXP
carbendazim results in increased expression of MIR128-1 mRNA
CTD
PMID:32418910
NCBI chr13:44,916,534...44,916,615
Ensembl chr13:44,916,534...44,916,615
G
Mir423
microRNA 423
increases expression
EXP
carbendazim results in increased expression of MIR423 mRNA
CTD
PMID:32418910
NCBI chr10:63,098,366...63,098,444
Ensembl chr10:63,098,360...63,098,453
G
Mmp2
matrix metallopeptidase 2
decreases expression
ISO
carbendazim results in decreased expression of MMP2 mRNA
CTD
PMID:25530041
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
G
Mmp9
matrix metallopeptidase 9
decreases expression
ISO
carbendazim results in decreased expression of MMP9 mRNA
CTD
PMID:25530041
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
G
Nfe2l2
nuclear factor, erythroid 2-like 2
increases expression
ISO
carbendazim results in increased expression of NFE2L2 protein
CTD
PMID:30851412
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
G
Nr1h4
nuclear receptor subfamily 1, group H, member 4
multiple interactions
ISO
carbendazim inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
CTD
PMID:25257666
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
G
Pim1
Pim-1 proto-oncogene, serine/threonine kinase
increases expression
EXP
carbendazim results in increased expression of PIM1 mRNA
CTD
PMID:22952946
NCBI chr20:8,165,423...8,169,557
Ensembl chr20:8,165,307...8,169,555
G
Plau
plasminogen activator, urokinase
decreases expression
ISO
carbendazim results in decreased expression of PLAU mRNA
CTD
PMID:25530041
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
G
Ptgds
prostaglandin D2 synthase
decreases expression
EXP
carbendazim results in decreased expression of PTGDS mRNA
CTD
PMID:22952946
NCBI chr 3:2,686,125...2,689,059
Ensembl chr 3:2,686,123...2,689,084
G
Serpine2
serpin family E member 2
increases expression
ISO
carbendazim results in increased expression of SERPINE2 mRNA
CTD
PMID:25530041
NCBI chr 9:85,560,852...85,629,410
Ensembl chr 9:85,560,863...85,626,094
G
Shank3
SH3 and multiple ankyrin repeat domains 3
multiple interactions
EXP
[carbendazim co-treated with 2,5-hexanedione] affects the expression of SHANK3 mRNA
CTD
PMID:22382377
NCBI chr 7:130,474,278...130,534,679
Ensembl chr 7:130,474,279...130,534,679
G
Sil1
SIL1 nucleotide exchange factor
decreases expression
EXP
carbendazim results in decreased expression of SIL1 mRNA
CTD
PMID:22952946 PMID:27466211
NCBI chr18:28,067,476...28,302,008
Ensembl chr18:28,067,484...28,301,863
G
Sod3
superoxide dismutase 3
increases expression
EXP
carbendazim results in increased expression of SOD3 mRNA
CTD
PMID:27466211
NCBI chr14:60,958,583...60,971,143
Ensembl chr14:60,958,592...60,964,324
G
Srebf1
sterol regulatory element binding transcription factor 1
increases expression
ISO
carbendazim results in increased expression of SREBF1 mRNA
CTD
PMID:26071454
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
G
Tbc1d5
TBC1 domain family, member 5
decreases expression
EXP
carbendazim results in decreased expression of TBC1D5 mRNA
CTD
PMID:27466211
NCBI chr 9:1,144,641...1,747,732
Ensembl chr 9:1,145,700...1,746,397
G
Timp1
TIMP metallopeptidase inhibitor 1
increases expression
ISO
carbendazim results in increased expression of TIMP1 mRNA
CTD
PMID:25530041
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
G
Timp2
TIMP metallopeptidase inhibitor 2
increases expression
ISO
carbendazim results in increased expression of TIMP2 mRNA
CTD
PMID:25530041
NCBI chr10:107,338,465...107,386,072
Ensembl chr10:107,338,465...107,386,072
G
Tnp1
transition protein 1
increases expression
EXP
carbendazim results in increased expression of TNP1 mRNA
CTD
PMID:28576679
NCBI chr 9:80,294,837...80,295,446
Ensembl chr 9:80,294,840...80,295,446
G
Tnp2
transition protein 2
increases expression
EXP
carbendazim results in increased expression of TNP2 mRNA
CTD
PMID:28576679
NCBI chr10:4,953,898...4,954,626
Ensembl chr10:4,953,879...4,954,624
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all